Healthy Skepticism Library item: 8604

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Jensen GB, Hampton J.
Early termination of drug trials
BMJ 2007 Feb 17; 334:(7589):326
http://www.bmj.com/cgi/content/short/334/7589/326?etoc

Abstract:

What are the ramifications for drug companies and drug safety monitoring boards?

In December 2006 a randomised controlled trial of torcetrapib (a cholesteryl ester transfer protein inhibitor aimed at increasing high density lipoprotein cholesterol) was stopped after an unexpected increase in mortality in people taking the drug.1 The implications are widespread, ranging from the future direction of cardiovascular prevention, the willingness of drug companies to develop new drugs in the face of massive financial risk, to the role of data and safety monitoring boards.

More than 12% of global mortality is caused by coronary heart disease.2 Reduction of low density lipoprotein cholesterol with statins has been successful in primary and secondary prevention of such disease, although mortality rates remain high. Because high density lipoprotein cholesterol is inversely associated with risk of cardiovascular disease, much investment has gone into newer drugs that increase concentrations of high density lipoprotein cholesterol (such as torcetrapib).

Phase II trials found that torcetrapib increases high density . . .

Keywords:
PMID: 17303842 [PubMed - in process]